Announcements Trials
Browse Landscape

Phase

Phase 3 4Phase 2 2Phase 1 2

Status

Completed 2Withdrawn 1Active not recruiting 1

Sponsor Class

INDUSTRY 3NETWORK 1

Study Type

Interventional 4

Sponsor

Cancer Type

Gynecologic 4

Conditions

Carcinoma, Non-Small-Cell Lung 35Breast Neoplasms 34Lung Neoplasms 20Triple Negative Breast Neoplasms 6Neoplasm Metastasis 5Adenocarcinoma of Lung 5Uterine Cervical Neoplasms 4Rhabdomyosarcoma 3Neoplasms 3NSCLC 3Hodgkin Disease 3Rhabdomyosarcoma, Embryonal 2Rhabdomyosarcoma, Alveolar 2Recurrence 2Adenocarcinoma 2Thoracic Neoplasms 1Sarcoma 1Respiratory Tract Neoplasms 1Respiratory Tract Diseases 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Non - Small Cell Lung Cancer NSCLC 1Neuralgia 1Metastatic HER2-positive Breast Cancer 1Mesothelioma, Malignant 1Malignant mesenchymal tumor 1Lymphoma, Non-Hodgkin 1Lymphoma 1Lung Diseases 1HR+HER2- Breast Cancer 1HER2-positive Advanced Breast Cancer 1

Interventions

Cisplatin 53Paclitaxel 27Carboplatin 22Brachytherapy 18Radiotherapy 17human papillomavirus vaccine, L1 type 16, 18 12Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 12Gemcitabine 12Topotecan 8Vaccines, Synthetic 7Platinum 7Papillomavirus Vaccines 7Radiation 6Bevacizumab 61,2-diaminocyclohexaneplatinum II citrate 6Neoadjuvant Therapy 5Chemotherapy, Adjuvant 5pembrolizumab 4Vinorelbine 4Radiotherapy, Intensity-Modulated 4Pemetrexed 4Drug Therapy 4Taxes 3Surgical Procedures, Operative 3Ondansetron 3Irinotecan 3Dexamethasone 3Chemoradiotherapy 3tisotumab vedotin 2specific substance maruyama 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 3 × Uterine Cervical Neoplasms × Vinorelbine × Clear all
NCT06459180 2026-05-27

TroFuse-020

Merck Sharp & Dohme LLC

Phase 3 Active not recruiting
686 enrolled
Gynecologic

Uterine Cervical Neoplasms

NCT04697628 2026-02-24

innovaTV 301

Seagen Inc.

Phase 3 Completed
502 enrolled 18 charts 1 FDA
Gynecologic

Uterine Cervical Neoplasms

NCT04943627 2022-10-05

Balstilimab Versus Investigator Choice Chemotherapy in Patients With Recurrent Cervical Cancer (BRAVA)

Agenus Inc.

Phase 3 Withdrawn
Gynecologic

Uterine Cervical Neoplasms

NCT00064077 2018-10-17

Comparison of Four Combination Chemotherapy Regimens Using Cisplatin in Treating Patients With Stage IVB, Recurrent, or Persistent Cancer of the Cervix

GOG Foundation

Phase 3 Completed
513 enrolled 15 charts
Gynecologic

Uterine Cervical Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡